Hatteras Venture Partners led a $15.9m Series A round in Ten63 Therapeutics.

Hatteras Venture Partners, a capital venture firm, led a $15.9m Series A round in Ten63 Therapeutics, a biotechnology company, with the participation from SOSV, Morpheus Ventures, Draper Associates, Alexandria Venture Investments, and Sigma Capital. “We are thrilled to welcome some of the leading biotechnology and technology venture funds to accelerate our pipeline and platform. At Ten63, we are dedicated to developing groundbreaking therapeutics that benefit patients, and we are pleased to strengthen our syndicate with the experience and expertise to help us get there. Our investors have repeatedly demonstrated the ability to help companies grow to have a positive impact on patients’ lives. We look forward to building on that tradition,” Marcel Frenkel, PhD, Ten63 CEO.